CATALOGO DEI PRODOTTI DELLA RICERCA

MILELLA, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.957
AS - Asia 6.942
EU - Europa 6.731
SA - Sud America 1.128
AF - Africa 171
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 8
AN - Antartide 1
Totale 22.965
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.763
SG - Singapore 2.997
CN - Cina 1.898
IT - Italia 1.020
BR - Brasile 995
HK - Hong Kong 988
GB - Regno Unito 883
DE - Germania 873
FR - Francia 842
RU - Federazione Russa 812
IE - Irlanda 708
SE - Svezia 568
FI - Finlandia 450
KR - Corea 307
VN - Vietnam 191
NL - Olanda 161
ID - Indonesia 151
CA - Canada 125
AT - Austria 85
UA - Ucraina 79
IN - India 78
PL - Polonia 66
JP - Giappone 52
TG - Togo 51
ES - Italia 41
TR - Turchia 39
MX - Messico 37
BD - Bangladesh 36
AR - Argentina 34
ZA - Sudafrica 33
CZ - Repubblica Ceca 32
TH - Thailandia 24
AU - Australia 23
EG - Egitto 22
IR - Iran 22
CO - Colombia 20
PK - Pakistan 20
BE - Belgio 19
IQ - Iraq 18
UZ - Uzbekistan 17
VE - Venezuela 17
MA - Marocco 16
EC - Ecuador 15
PE - Perù 12
PY - Paraguay 11
TN - Tunisia 11
CH - Svizzera 10
CL - Cile 10
LT - Lituania 10
MY - Malesia 10
UY - Uruguay 10
AE - Emirati Arabi Uniti 9
SA - Arabia Saudita 9
AZ - Azerbaigian 8
EU - Europa 7
KE - Kenya 7
KG - Kirghizistan 7
LU - Lussemburgo 7
AM - Armenia 6
AO - Angola 6
GT - Guatemala 6
HR - Croazia 6
LV - Lettonia 6
NP - Nepal 6
RO - Romania 6
SK - Slovacchia (Repubblica Slovacca) 6
TW - Taiwan 6
BG - Bulgaria 5
CR - Costa Rica 5
DZ - Algeria 5
IL - Israele 5
JO - Giordania 5
PH - Filippine 5
PT - Portogallo 5
BY - Bielorussia 4
DK - Danimarca 4
HN - Honduras 4
JM - Giamaica 4
KH - Cambogia 4
KZ - Kazakistan 4
LA - Repubblica Popolare Democratica del Laos 4
MK - Macedonia 4
PS - Palestinian Territory 4
SN - Senegal 4
CU - Cuba 3
DO - Repubblica Dominicana 3
GR - Grecia 3
NO - Norvegia 3
PA - Panama 3
AL - Albania 2
BH - Bahrain 2
BO - Bolivia 2
BW - Botswana 2
CY - Cipro 2
GA - Gabon 2
GM - Gambi 2
HU - Ungheria 2
LK - Sri Lanka 2
ME - Montenegro 2
MZ - Mozambico 2
Totale 22.932
Salva come PNG Salva come JPEG
Città #
Dallas 1.546
Singapore 1.286
Chandler 1.264
Hong Kong 977
Southend 738
Dublin 685
Ashburn 412
Beijing 373
Verona 354
Munich 341
Woodbridge 333
Jacksonville 301
Lawrence 267
Princeton 267
Ann Arbor 197
Helsinki 189
Sindelfingen 185
Houston 174
New York 151
Jakarta 141
Redmond 139
Wilmington 135
Jinan 134
The Dalles 129
Turku 87
Milan 85
Nanjing 84
Shenyang 82
São Paulo 82
Columbus 81
Los Angeles 81
Nuremberg 71
Hebei 61
Seattle 61
Santa Clara 60
Toronto 57
Frankfurt am Main 52
Lomé 51
Tianjin 49
Ningbo 45
Tokyo 44
San Francisco 43
Ho Chi Minh City 41
Vienna 41
Chicago 40
Seoul 40
Changsha 39
Zhengzhou 39
Amsterdam 38
Guangzhou 38
Lappeenranta 38
Council Bluffs 36
London 36
Hangzhou 33
Boardman 31
Haikou 31
Hanoi 31
Kent 31
Nanchang 31
Brooklyn 30
Rio de Janeiro 30
Belo Horizonte 29
Dong Ket 29
Moscow 29
Taiyuan 28
Washington 28
Rome 27
Redwood City 25
Taizhou 25
Warsaw 25
Fuzhou 22
Jiaxing 22
Atlanta 21
Bangkok 21
Falkenstein 21
Shanghai 21
Andover 20
Brno 20
Johannesburg 20
Lanzhou 20
Brussels 19
Montreal 19
Ankara 18
Dongguan 18
Boston 17
Stockholm 17
Tashkent 17
Chennai 16
Ottawa 16
Curitiba 15
Fairfield 14
Brescia 13
Campinas 13
Porto Alegre 13
Cedar Knolls 12
Falls Church 12
Bologna 11
Brasília 11
Denver 11
Maceió 11
Totale 13.314
Salva come PNG Salva come JPEG
Nome #
Assessment of Psychological Burden in Individuals with Hereditary Risk of Pancreatic Cancer Under Surveillance: Evaluation of Distress 3 Years After Enrollment 259
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 216
Genomic characterization of hepatoid tumors: context matters 169
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 162
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 154
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 143
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 143
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models 142
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 141
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 141
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 129
ERK 1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia 126
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 125
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer 125
"Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms 124
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 123
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen 120
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 119
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models 116
Acinar Cystic Transformation of the Pancreas: Histomorphology and Molecular Analysis to Unravel its Heterogeneous Nature 115
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 115
Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19 115
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 112
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 111
Sex differences in oncogenic mutational processes 110
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 110
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 109
Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder 108
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours 107
Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? 107
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions 107
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 105
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples 103
Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma 102
Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer 102
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss 101
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 101
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma 101
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 101
A multimodal approach to cancer-related cachexia: from theory to practice 101
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode 100
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 100
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 99
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 99
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 98
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 98
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 97
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 97
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma 96
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 96
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 96
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 95
An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change? 93
Do immune checkpoint inhibitors need new studies methodology? 93
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 93
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 93
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 92
Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial 92
Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer 91
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 91
Exercise levels and preferences in cancer patients: a cross-sectional study 91
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets 91
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules 90
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 89
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer 89
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 89
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 89
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. 88
Pan-cancer analysis of whole genomes 88
The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer 88
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 88
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 88
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 87
Muscle derangement and alteration of the nutritional machinery in NSCLC 86
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 86
Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar 86
DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association 86
Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment 85
Aromatase inhibitors in post-menopausal metastatic breast carcinoma 85
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? 85
The Italian Rare Pancreatic Exocrine Cancer Initiative 85
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 85
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias 85
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 85
A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study 84
The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome 84
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma 84
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 84
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 84
Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites 84
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 83
Autoantibody signature in human ductal pancreatic adenocarcinoma 83
Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward 83
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 82
Loss of FGFR4 promotes the malignant phenotype of PDAC 80
Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients 80
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 80
18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study 80
Case report: Male genital system, soft tissue and myocardial metastases in a patient with exon 11-mutated GIST of unknown origin 80
Novel Clinical Prognostic Score Incorporating the Number of Resected Lymph-Nodes to Predict Recurrence and Survival in Non-Small-Cell Lung Cancer. 79
Totale 10.337
Salva come PNG Salva come JPEG
Categoria #
all - tutte 113.435
article - articoli 112.473
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 156
patent - brevetti 0
selected - selezionate 0
volume - volumi 806
Totale 226.870
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021759 0 0 52 122 146 119 37 34 43 25 110 71
2021/20221.789 110 378 60 108 46 22 37 103 59 37 310 519
2022/20234.070 290 364 383 714 323 1.057 61 223 440 49 105 61
2023/20242.607 91 167 234 360 225 356 206 191 56 126 419 176
2024/20257.962 438 354 332 1.393 349 302 437 439 1.112 629 730 1.447
2025/20263.969 1.501 1.258 1.210 0 0 0 0 0 0 0 0 0
Totale 23.472